AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00728000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100mg/day PO on days 1-14 and 15-28
Study NCT04751136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cerebrolysin
Description: Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
Study NCT01287728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment BY METROMIDAZOLE
Description: Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole
Study NCT04120142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation+IMT
Description: The experimental group receives inspiratory muscle training and aerobic exercise.
Study NCT04120142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: The Active Comparator group received only aerobic exercise.
Study NCT00377988 — intervention group
Intervention type: DRUG
Intervention: Transdermal Contraceptive System
Description: In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
Study NCT00377988 — intervention group
Intervention type: DRUG
Intervention: Norgestimate-containing oral contraceptives with EE
Description: NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
Study NCT01210378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch
Description: Nitroglycerin patch
Study NCT03258671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: ·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;
Study NCT03258671 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: High dose group：DTGTV=70Gy；~* first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。~Low dose group：DTGTV=50Gy;~* first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。
Study NCT04368832 — intervention group
Intervention type: OTHER
Intervention: Remote consultation
Description: One or more consultation is conducted by phone or teleconsultation during prenatal monitoring
Study NCT03994237 — intervention group
Intervention type: OTHER
Intervention: semi-structured interview
Description: The tool used is a nurse card: there is no validated tool on the expectations of the caregiver in his memory referral. This is a pragmatic and practical questionnaire memory consultation request and domestic life with few items, practical use by telephone.
Study NCT03485703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
Study NCT03485703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the group of newborns will receive 0.9% saline once daily for 5 days
Study NCT01470144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoprostenol
Description: Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
Study NCT02851212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
Study NCT02851212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablets) under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Study NCT02851212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Study NCT02851212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Study NCT02612545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Description: Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
Study NCT02612545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Description: Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
Study NCT02612545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Description: ACT partner drug
Study NCT02392702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10355
Study NCT02392702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10358
Study NCT02392702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kalydeco
Study NCT00235248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin
Study NCT00235248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin
Description: Clopidogrel-aspirin
Study NCT05194852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided posterior hydrodilatation
Description: Group I was treated through posterior approach; The injection needle is introduced at the skin surface just lateral to the transducer and in an oblique lateral to medial direction. Group II was treated through anterior rotator interval approach. A 21-gauge needle is introduced into the rotator interval using an oblique path within the imaging plane of the transducer; from lateral to medial, the needle tip is imaged in real time throughout its passage from superficial to deep and is positioned in the biceps tendon sheath between the coracohumeral ligament above and biceps tendon below. Both groups were given the same guided stretching and strengthening exercise program
Study NCT05194852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided posterior hydrodilatation
Description: Group I was treated through posterior approach; The injection needle is introduced at the skin surface just lateral to the transducer and in an oblique lateral to medial direction. Group II was treated through anterior rotator interval approach. A 21-gauge needle is introduced into the rotator interval using an oblique path within the imaging plane of the transducer; from lateral to medial, the needle tip is imaged in real time throughout its passage from superficial to deep and is positioned in the biceps tendon sheath between the coracohumeral ligament above and biceps tendon below. Both groups were given the same guided stretching and strengthening exercise program
Study NCT05194852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid, saline, and local anesthetic
Description: corticosteroid, saline, and local anesthetic
Study NCT05194852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: guided stretching and strengthening exercise program
Description: guided stretching and strengthening exercise program
Study NCT05194852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guided stretching and strengthening exercise program
Description: guided stretching and strengthening exercise program
Study NCT03029845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol 1
Description: Participants will take 20 mg propranolol twice a day for 2 weeks
Study NCT03029845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol 2
Description: Participants will take 10 mg propranolol twice a day for 2 weeks
Study NCT03029845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo twice a day for 2 weeks
Study NCT03301831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training
Description: Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
Study NCT03171740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine, 1mcg/kg (it is a 100mcg/ml solution)
Study NCT03171740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam oral solution
Description: Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)
Study NCT03171740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral saline
Description: Oral saline, 0.25ml/kg
Study NCT03171740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal saline
Description: Nasal saline 0.01ml/kg
Study NCT02185807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video-assisted group
Description: The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians.
Study NCT02185807 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: The control patients receive verbal information and discussion from their physicians.
Study NCT04509817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture+Usual care
Description: Acupuncture intervention Disposable, sterilized needles (0.25×40 mm and 0.30×50 mm) will be used and selected acupoints will include GV20, CV4, and bilateral BL32, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9. Subject will be prone position first and BL32 will be inserted with an angle of 30-45° in an inferomedial direction and a depth of 30-50 mm. Once the subject has a needle sensation ('De-qi'), the needle will be removed immediately. Then the subject will be supine position, and GV20, CV4, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9 will be needled with a depth of 10-40mm. After subject feel 'De-qi', the needles will be placed for 20 min to maintain the stimulation.~Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise.~Behavioral: Usual care Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise.
Study NCT04509817 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care intervention The subjects will receive the health advice
Study NCT05713162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004).
Description: The social skills intervention program was based on a consented adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004). In order to be feasible in a hospital-based service, we adapted the program to 10 sessions. Session structure included initial greeting, free play time, didactic, joke telling, and closing activities. Topics of didactic sessions were related to social competence, such as empathy, talking about feelings, and solving social problems. We also adapted the content of the sessions, including activities proposed by Solomon (2004) but also from other experts in social cognition, such as García-Winner (2000). Each group was comprised by 7-10 participants. Children groups were conducted by a clinical psychologist, a mental health nurse and the support of two master degree students. Adolescent groups were conducted by a psychologist, a psychiatrist and the support of two master degree students.
Study NCT01613963 — intervention group
Intervention type: DRUG
Intervention: Immunosuppressive Agents
Description: Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
Study NCT02698306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT02698306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Diclofenac Sodium
Study NCT02386878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Groups (IPTG)
Description: Interpersonal psychotherapy is a theory- and evidence-based treatment approach for depression developed by clinicians. World Vision has helped to pioneer the use of this model in sub-Saharan Africa including adapting the model for use with OVC within South Africa. Sessions are designed to provide participants with opportunities to learn and practice interpersonal skills for solving problems that bring about depression, and to facilitate the provision of emotional support between members of the group. Groups are implemented by a trained adult facilitator from the community who helps participants to identify people who are important in their lives, understand links between their psychological state and current problems, and practice new ways of problem-solving.
Study NCT02386878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vhutshilo 2
Description: The Vhutshilo 2 model was developed in 2008 by the Centre for the Support of Peer Education (CSPE), a branch of the South African non-profit organization Health and Education Training and Technical Assistance Services. The Vhutshilo program was designed specifically for adolescent OVC in South Africa, and attends to risk factors and pathways considered particularly relevant for this population. Topics include finding and giving emotional support; dealing with grief and loss; alcohol and substance abuse; crime and sexual violence; HIV/AIDS; healthy and safe sexual relationships; and transactional sex. In addition to its knowledge component, the program places heavy emphasis on building relevant skills and efficacy.
Study NCT01991145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood therapy
Description: HLA (Human Leukocyte Antigen) typing
Study NCT01991145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood therapy
Description: HLA (Human Leukocyte Antigen) typing
Study NCT01991145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erythropoietin alfa
Study NCT01991145 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin alfa
Study NCT01991145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Active rehabilitation
Study NCT01991145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Active rehabilitation
Study NCT01991145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: Active rehabilitation
Study NCT01991145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo UCB
Study NCT01991145 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo UCB
Study NCT01991145 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo EPO
Study NCT01991145 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EPO
Study NCT02271230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D and fish oil
Description: 2000 IU vitamin D and 1g/d fish oil
Study NCT02271230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil (EPA/DHA) alone
Description: 1 g/d fish oil
Study NCT02271230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D alone
Description: 2000 IU vitamin D
Study NCT02271230 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin D placebo and fish oil placebo
Study NCT02489409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndostarTM Injection
Description: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
Study NCT02489409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1.0 m/m2, iv 0.5h, d1, 8
Study NCT02489409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1.0 m/m2, iv 0.5h, d1, 8
Study NCT02489409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Navelbine
Description: 40 mg/d, iv, d1, 8
Study NCT02489409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navelbine
Description: 40 mg/d, iv, d1, 8
Study NCT02489409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum
Description: 30 mg/m2, iv 3h, d1-3
Study NCT02489409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: 30 mg/m2, iv 3h, d1-3
Study NCT02489409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeloda Tablets:
Description: 2 000 mg/m2, po, d1-14
Study NCT02489409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda Tablets:
Description: 2 000 mg/m2, po, d1-14
Study NCT00020722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.~The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion.
Study NCT00020722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide, carboplatin, and etoposide (ICE) regimen
Description: Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2
Study NCT00020722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)
Description: Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2.
Study NCT00020722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.
Study NCT00020722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation (PBSCT)
Description: Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
Study NCT02121327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: disease management
Description: disease management program include self management education
Study NCT02121327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: usual care group receive regular outpatient treatment
Study NCT02121327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care group receive regular outpatient treatment
Study NCT04555005 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness based intervention
Description: Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
Study NCT03191071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: UltraPro
Description: First, procalcitonin will be measured using a rapid point-of-care test. In case of elevated procalcitonin result (≥0.25 µg/L), a lung ultrasound will be performed to look for the presence of a lung infiltrate or consolidation suggesting the presence of community acquired pneumonia. A portable ultrasound machine with a convex probe, that will be provided to the general practitioner by the study, will be used.~The lung ultrasound will be done following international evidence-based recommendations for point-of-care lung ultrasound using the basic eight-region sonographic technique and the criteria for positive scan and positive examination for the diagnosis of pneumonia .